



Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright 
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
 Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
 You may not further distribute the material or use it for any profit-making activity or commercial gain 
 You may freely distribute the URL identifying the publication in the public portal 
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
  
 
   
 
 
Downloaded from orbit.dtu.dk on: Mar 30, 2019
How Synthetic Biology and Metabolic Engineering Can Boost the Generation of
Artificial Blood Using Microbial Production Hosts
Frost, August T. ; Jacobsen, Irene Hjorth; Worberg, Andreas; Martinez Ruiz, José Luis
Published in:
Frontiers in Bioengineering and Biotechnology





Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Frost, A. T., Jacobsen, I. H., Worberg, A., & Martinez , J. L. (2018). How Synthetic Biology and Metabolic
Engineering Can Boost the Generation of Artificial Blood Using Microbial Production Hosts. Frontiers in
Bioengineering and Biotechnology, 6, [186]. DOI: 10.3389/fbioe.2018.00186
MINI REVIEW
published: 30 November 2018
doi: 10.3389/fbioe.2018.00186







University of Valencia, Spain
Pasquale Stano,





This article was submitted to
Synthetic Biology,
a section of the journal
Frontiers in Bioengineering and
Biotechnology
Received: 28 September 2018
Accepted: 15 November 2018
Published: 30 November 2018
Citation:
Frost AT, Jacobsen IH, Worberg A and
Martínez JL (2018) How Synthetic
Biology and Metabolic Engineering
Can Boost the Generation of Artificial
Blood Using Microbial Production
Hosts.
Front. Bioeng. Biotechnol. 6:186.
doi: 10.3389/fbioe.2018.00186
How Synthetic Biology and Metabolic
Engineering Can Boost the
Generation of Artificial Blood Using
Microbial Production Hosts
August T. Frost 1, Irene H. Jacobsen 1, Andreas Worberg 2 and José L. Martínez 1*
1 Section of Synthetic Biology, Department of Biotechnology and Biomedicine, Technical University of Denmark (DTU), Lyngby,
Denmark, 2Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark (DTU), Lyngby, Denmark
Hemoglobin is an essential protein to the human body as it transports oxygen to organs
and tissues through the bloodstream (Looker et al., 1992). In recent years, there has
been an increasing concern regarding the global supply of this vital protein, as blood
availability cannot currently meet the high demands in many developing countries.
There are, in addition, several risks associated with conventional blood transfusions
such as the presence of blood-borne viruses like HIV and Hepatitis. These risks along
with some limitations are presented in Figure 1 (Kim and Greenburg, 2013; Martínez
et al., 2015). As an alternative, producing hemoglobin recombinantly will eliminate the
obstacles, since hemoglobin-based oxygen carriers are pathogen-free, have a longer
shelf-life, are universally compatible and the supply can be adjusted to meet the demands
(Chakane, 2017). A stable, safe, and most importantly affordable production, will lead to
high availability of blood to the world population, and hence reduce global inequality,
which is a focus point of the World Health Organization for the millennium (WHO,
2018). Synthetic biology and metabolic engineering have created a unique opportunity
to construct promising candidates for hemoglobin production (Liu et al., 2014; Martínez
et al., 2016). This review sets out to describe the recent advances in recombinant
hemoglobin production, the societal and the economic impact along with the challenges
that researchers will face in the coming years, such as low productivity, degradation, and
difficulties in scale-up. The challenges are diverse and complex but with the powerful
tools provided by synthetic biology and metabolic engineering, they are no longer
insurmountable. An efficient production of cell-free recombinant hemoglobin poses
tremendous challenges while having even greater potential, therefore some possible
future directions are suggested in this review.
Keywords: synthetic biology, metabolic engineering, yeast, protein production, blood substitutes, HBOC,
recombinant hemoglobin
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FIGURE 1 | The limitations to conventional blood transfusions. The limitations are divided into three distinct groups; (a) limitations in storage and shelf life, (b)
limitations due to donor dependency, blood-borne diseases, and incompatibility of blood types, and (c) limitations due to religious beliefs.
HISTORICAL PERSPECTIVE—SOCIETAL
AND MEDICAL NEEDS
Since the first recorded blood transfusion in the ancient
Inca civilization (fifteenth century), there have been countless
attempts to create alternative blood substitutes to further
improve the chance of surviving anemia (Sarkar, 2008). In the
dawn of this development, elementary liquids such as sheep
blood, urine, and beer were tested for the possibility to be a
substitute for human blood. In the late nineteenth century, even
cow milk was injected into patients with the belief that it would
help regenerate white blood cells (Chen et al., 2009).
The earliest report of a hemoglobin-based blood substitute
originates from the beginning of the 1930s, however it was
not until 1957 that the first study on an artificial red blood
cell composed by microencapsulated hemoglobin was performed
(Li et al., 2005). After a stagnant period, the advancement was
significantly stimulated by the onset of AIDS, hepatitis, and
HIV infections in the 1980s, which imposed a radical risk to
conventional blood transfusions (Kim and Greenburg, 2013;
Martínez et al., 2015). Consequently, the following period was a
golden age for the development of artificial substitutes that would
be able to mimic the oxygen-carrying property of erythrocytes
(Varnado et al., 2013; Martínez et al., 2015).
Through history, the pursuit of artificial blood substitutes
has been heavily funded by the military to eliminate the supply,
storage, and portability problems associated with human blood.
However, the societal and medical need to find an alternative
to conventional blood transfusion has escalated in recent years,
especially in developing countries (Kim and Greenburg, 2013;
Moradi et al., 2016). This is due to factors such as population
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growth, natural disasters, decreasing donor number, population
aging, terror attacks, and the risk of blood-borne pathogens
threatening the supply-demand balance of human blood (Looker
et al., 1992; Varnado et al., 2013; Alayash, 2014; Moradi et al.,
2016; Chakane, 2017).
The development of blood substitutes furthermore has the
potential to get rid of logistical barriers for pre-hospital use in
acute emergency situations and remote civilian locations, by
enabling long-term storage, eliminating blood type matching,
supplying adequate quantities, be “pathogen-free,” and
providing immediate availability in catastrophic scenarios
(Chakane, 2017).
RECENT ADVANCES
Recent breakthroughs in the fields of synthetic biology
and metabolic engineering have substantially boosted the
development of the so-called oxygen carriers, which can be
divided into two main categories: perfluorocarbon-based
substitutes (PFC) and hemoglobin-based oxygen carriers
(HBOCs) (Mozafari et al., 2015). While the research in the
PFC as blood substitutes has been partially discontinued, due
to their limited oxygen transfer capacity to tissues and toxicity
problems, the capacity of HBOCs to mimic red blood cells in
terms of oxygen transport while being less toxic, has put the
focus on them. Hemoglobin supply is, therefore, the first key
issue for the successful development of the latter. The primary
sources of hemoglobin for the current development of HBOCs
are expired human blood, mammalian hemoglobins formed as
a by-product in the meat industry (e.g., bovine hemoglobin),
and recombinant hemoglobin produced in transgenic organisms
(Motwani et al., 1996; Sanders et al., 1996; Varnado et al.,
2013; Alayash, 2014; Moradi et al., 2016). The two first options
are not the optimal choices, as their availability is too limited
to allow a substantial development in HBOCs research. It
is paramount for the case of the recombinant hemoglobin
production, that new production hosts are designed with an
increased and more efficient production capacity. Here, synthetic
biology and metabolic engineering are key role players, both in
terms of designing better cell factories and achieving affordable
production costs.
Escherichia coli was the first choice as production workhorse.
On a first attempt, a single β-globin chain with a cleavable
linker was expressed, and subsequently refolded in vitro with
a native α-globin chain and exogenous heme (Nagai and
Thøgersen, 1987). In a follow-up experimental setup, α-globin
and β-globin chains were co-expressed in vivo with endogenous
heme incorporated (Shen et al., 1993). Although recombinant
hemoglobin was successfully produced in bacteria, later advances
focused on eukaryal hosts, as a result of the discovery that the
vital functions of the hemoglobin produced by bacterial hosts
were altered, most likely due to the methionine termini at the
end of the globin chains. The alterations were identified to
be caused by reduced Bohr effect and 2,3-BPG effects of the
produced recombinant hemoglobin compared to normal human
hemoglobin (Hoffman et al., 1990).
Thus, the production shifted to themodel yeast Saccharomyces
cerevisiae. Since then, synthetic biology and metabolic
engineering have been applied to modify the heme biosynthetic
pathway by overexpressing the genes coding for enzymes
responsible for the rate-limiting steps (e.g.,HEM3). Furthermore,
the optimal globin expression balance between α and β chains
was studied. In combination, the recombinant hemoglobin
production was improved by an impressive 87% (Liu et al., 2014)
compared to the previous attempts.
Important key issues to take into consideration, in order
to get further in the advancement of HBOCs, apart from the
sustained hemoglobin supply, are the safety concerns and cost-
effectiveness. Non-clinical and clinical studies of HBOCs have
raised safety concerns regarding hemoglobin extravasation across
the blood vessel wall, scavenging of endothelial nitric oxide,
oversupply of oxygen, and oxidative side reactions (Alayash,
2014). As a result, the regulatory agencies in the United States and
the European Union have not yet approved any HBOCs (Chen




A study performed in the United States have estimated that it is
currently possible to produce recombinant human hemoglobin at
a cost of approximately $11/g. However, if the operating expenses
and equipment investments are included, the cost increases to a
dazzling amount of≥$200/g. In comparison, human hemoglobin
can be derived from alternative sources for roughly $2/g to $4/g
(excl. post-related costs) based on fixed reimbursement prices of
whole blood packs (Varnado et al., 2013).
There is, consequently, a demanding need to significantly
improve the cost-effectiveness by either reducing the production
cost or increasing the expression yield of recombinant
hemoglobin by more than 3-fold to be cost-effective against
alternatives. Synthetic biology can contribute with further
optimizations to provide affordable recombinant hemoglobin
at a comparable price to alternatives in the future. WHO has
created a set of goals to improve global health for the world
population by 2020—these are called “HEALTH 2020” (WHO,
2018). Recombinant hemoglobin is extremely relevant to one
of the goals, which is to reduce inequality in the access to the
medicine of the twenty first century and save lives.
THE CHALLENGES OF RECOMBINANT
HEMOGLOBIN PRODUCTION
The evolution of synthetic biology has given researchers
the possibility to synthesize new genetic elements instead of
transferring them from a donor organism (Stephanopoulos,
2012). Nowadays entire genomes can be synthesized and inserted
into a host organism (Kuo et al., 2018). Biotechnological research
has also benefited from synthetic biology, as it synergizes
with metabolic engineering. Synthetic biology provides genetic
switches, vectors, characterized enzymes, and minimal hosts, all
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of which minimizes the cost and the time needed for metabolic
engineering (Keasling, 2012).
To successfully engineer novel cell factories a number
of frameworks can be applied, one of the most popular is
the “Design-Build-Test-Learn” cycle—Figure 2. The cycle is
an iterative process divided into four phases, which aims
at satisfying a set of predetermined specifications. The first
phase is the “Design”-phase where the organism is designed
in silico. That design is then constructed in the “Build”-phase.
The third phase is the “Test”-phase, where the organism or
construct is tested in terms of productivity, -omics, and growth
characteristics. The final part is the “Learn”-phase, where the
results from the “Test”-phase are evaluated and compared
to the predetermined specifications set in the “Design”-phase.
Often multiple iterations of the cycle are needed to achieve
the optimal organism and satisfy the specifications (Ando and
Martin, 2018; Jensen and Keasling, 2018). Synthetic biology and
metabolic engineering contribute mainly to the first two phases
(Nielsen and Keasling, 2016).
Higher Productivity
As previously described, the production of recombinant
hemoglobin from a heterologous host is not yet economically
feasible. Without accounting for operation cost and the expenses
of establishing the production plant, the estimated costs should
still be reduced by at least three-fold before being able to compete
on the market. One of the challenges is low productivity. In
2016, Martìnez et al. developed a recombinant S. cerevisiae-
based cell factory. After a few iterations of the DBTL cycle,
the constructed stain was able to synthesize functional human
hemoglobin with α-globin and β-globin genes expressed in the
optimal ratios, being the maximum measured concentration of
active human hemoglobin up to 7% of the total cell protein
content (Martínez et al., 2016). In perspective, this means that
this strain would be able to produce 200 kg of hemoglobin in a
100 m3 tank, assuming the highest theoretical yield. Considering
that one liter of human blood contains 150 grams of hemoglobin,
the equivalent to 1.300 liters of blood would be produced in one
batch. These are, however, ideal conditions in which upscaling
limitations and recovery of the product are not considered. To
reach these theoretical numbers at production-scale, a higher
productivity needs to be achieved in laboratory-scale. Enhancing
productivity in a heterologous organism is a task in the “Design”-
phase of the DBTL-cycle. Classically a lot of work would have to
be conducted, and a lot of manpower required, in order to plan
and test hypotheses which might lead to higher productivity. In
recent years, both the number and the variety of accurate open-
end genome-scale models have increased (Nielsen and Keasling,
2016). Applying these models to the rational design can save time
in the optimization of the productivity. It is now possible to find
a robust, open-end genome-scale model of S. cerevisiae, that can
be customized to have the genetic modifications implemented
in previous research. Different strategies can be executed, and
a simulation will reveal the success of the strategy in terms of
enhanced productivity. Bottlenecks and feedback inhibitions can
be identified and hence eliminated (Nielsen and Keasling, 2016).
Ultimately, only successful in-silico strategies will be carried out
experimentally.
Intracellular Degradation and Negative
Feedback Circuits
In the pursuit of higher productivities, most of the times
undesired trade-offs are found as a consequence. Normally,
degradation of precursors due to inherent feedback regulatory
reactions is the main issue, and recombinant hemoglobin
production is, unfortunately, not an exception to this matter.
Heme is essential to the yeast cell for signaling and co-factor
purposes, but it is also cytotoxic in higher concentrations as
it can originate reactive oxygen species (ROS). To prevent
accumulation and thereby toxicity, heme biosynthesis is tightly
controlled and coordinated with heme degradation in well-
understood processes (Martínez et al., 2016; Hanna et al., 2018).
When heme is bound in hemoglobin, ROS are no longer formed,
and heme will not be degraded (Liu et al., 2014).
A rapidly forming hemoglobin would therefore remove
un-bound heme from the mitochondrion and hence stop
degradation. Thus, the key is to have an abundance of
α and β chains ready for assembly. In the “Test”-phase,
proteomics combined with the advances in mass spectrometry,
can assist the quantification of the chains and thereby
identify possible limitations in the following “Learn”-phase
(Trent, 2012). Other ways to reduce degradation involve gene
knock-outs. For instance, genes involved in (i) iron-depletion
initiated degradation of heme to recover the iron (Philpott
and Protchenko, 2008) (ii) vacuolar miss-sorting and vacuolar
degradation of mature hemoglobin (Ammerer et al., 1986;
Marcusson et al., 1994; Hecht et al., 2014). Gene edition is tedious
and very limiting most of the times, however the introduction
and refining of the CRISPR-Cas9 system can drastically shorten
the duration of the “Build”-phases where multiple knock-outs or
insertions are needed. The method allows for gene disruption in
up to five different loci in S. cerevisiae with a high success rate.
The method is, moreover, marker-free (Jakocˇiunas et al., 2015).
Oxygen Limitation and Scale-Up
Hemoglobin synthesis in yeast is induced by high levels of
extracellular oxygen (Martínez et al., 2016). In production-scale
vessels adequate oxygen supply and transfer pose an issue due
to the low solubility of oxygen in submerged cultures. To ensure
a linear scale-up of oxygen availability other parameters need
to be modified, e.g., agitation which can lead to shear stress
(Reuss, 2008; Garcia-Ochoa and Gomez, 2009). Switching the
point of view from process engineering to genetic and metabolic
engineering could solve the problem. In 2015, Martìnez et al.
deleted a heme activator protein (HAP1) in S. cerevisiae and
found that heme production was increased due to the removal
of a feedback inhibition. Another measured effect of the HAP1
mutant is the reduction of respiration (Martínez et al., 2015). In
the ideal scenario a large-scale production could be established
based on a non-respiring strain where the presence of oxygen
would initiate heme synthesis. The feasibility of the strategy can
be predicted based on model-simulations rather than real-life
cultivations in production scale.
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FIGURE 2 | The Design-Build-Test-Learn cycle (DBTL-cycle). The “Design”-phase includes setting goals, choosing a host organism, using models and simulations,
and planning the design of the organism. In the “Build”-phase the organism is constructed based on the planned design. The “Test”-phase covers the in-depth testing
of the organism. The final phase is the “Learn”-phase where the results are analyzed and compared to the predetermined specifications.
Ethanol Production
The Crabtree-positive nature of S. cerevisiae (meaning its ability
to produce ethanol from glucose in aerobic conditions) is one
of the challenges in recombinant hemoglobin production for
several reasons: (i) lower yields as carbon is diverted into ethanol
production (Dai et al., 2018) and (ii) yields of hemoglobin
are lower on ethanol than on glucose (Liu et al., 2014). The
code to engineering a Crabtree-negative S. cerevisiae strain has
finally been cracked by a Dai et al. who used state-of-the-
art synthetic biology and molecular biology tools. The group
reverse engineered a strain which had evolved under Adapted
Laboratory Evolution. The created strain is the first Crab-
negative S. cerevisiae reported to be able to grow at high glucose
concentrations (Dai et al., 2018).
This particular strain in combination with the strategies stated
above could create the future S. cerevisiae-based hemoglobin
producer. Some challenges could arise as the Crabtree negative
S. cerevisiae needs mitochondrial respiration to reoxidize co-
factors, whereas it is beneficial to knock-out HAP1 to avoid
respiration in recombinant hemoglobin production (Martínez
et al., 2015; Dai et al., 2018). Simulations with an open-end
genome-scale model will disclose whether further design is
needed on co-factor reoxidizing or compartmentalization.
Recovery and Purification
Recovery and purification of hemoglobin from S. cerevisiae
differs from the challenges described above, as it requires a new
iteration of the DBTL-cycle. All the recombinant hosts designed
to date, store the produced hemoglobin intracellularly. To
recover the intracellular hemoglobin numerous unit operations
will be required (Bulmer et al., 1996; Stocker-Majd et al., 2008).
Here we will not discuss on how to solve the task by process
engineering, but rather the solutions that can be created by using
synthetic biology and metabolic engineering.
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The rational approach sounds simple: to secrete the
hemoglobin and recover it from the fermentation broth. All
though S. cerevisiae is a desired platform for heterologous protein
production, the yeast only secretes a few of its native proteins.
To successfully secrete hemoglobin the protein needs the correct
signal peptide, and genes involved in protein translocation
should be upregulated (Tang et al., 2015; Bao et al., 2017). The
combined powers of synthetic biology andmetabolic engineering
can decrease the amount of time and experiments needed.
Combinations of genes and signal peptides can be modeled
using genome-scale models to find the optima. The material
for the modifications can be synthetically generated or taken
directly from a BioBrick library (Constante et al., 2011) and
lastly, CRIPSR-Cas9 can serve as an efficient and marker-free
method for gene insertions or deletions (Jakocˇiunas et al.,
2015). However, it is a complex task to make multimeric
proteins secreted. Synthetic biology can contribute through the
design of novel protein structures that would facilitate secretion,
and hence the downstream processing, while keeping the
functional properties intact. As an example, there are currently
several strategies ongoing in order to design fusion hemoglobin
molecules as a single peptide, but keeping a domain-like structure
that resembles the multimeric structure.
Novel Production Hosts
Experimenting with novel organisms is no longer just a wish
from the researchers: new technologies have made the wish
come true. With BioBricks and minimal hosts, organisms can
be constructed and customized like mechanical objects—such
as airplanes (Constante et al., 2011; Keasling, 2012). BioBricks
are standardized which means that they are modular and can
be assembled in any way desired, and can be ordered from
the Standard Registry of Biological Parts which is a growing
collection (Constante et al., 2011). It is not farfetched to
envision that a paradigm shift will occur in the near future of
biotechnology. Researchers will be able to design the organism
that they want instead of working around native shortcomings.
All of these technologies can widen the array of possible cell
factories. For the production of recombinant hemoglobin this
means that the production platform will no longer be restricted
to S. cerevisiae. The performance of more organisms can be tested
out both theoretically (using models) and experientially (using
well-defined modular components) to find the optimal one. With
the recent advances in high through-put micro-fermentation
systems all-new stains can be designed, constructed and tested
rapidly (Kensy et al., 2009).
CONCLUDING REMARKS
The implementation and continuous development of synthetic
biology andmetabolic engineering tools have enabled researchers
to move the boundaries of what cell factories can do. The tools
cannot only be used for creating new “super-drugs” but also to
make well-known treatments more available.
Producing hemoglobin recombinantly in yeast has proven
feasible. The challenges which still remain are considered solvable
with the combined forces of knowledge, synthetic biology
and metabolic engineering. This review has described some
of the possible strategies to further improve yeast-based cell
factories.
Currently, commercial production of recombinant
hemoglobin is too expensive, to match the price of blood-
derived hemoglobin. The cost should be further decreased by
three-fold, but once strains have been optimized and large
production plants have been established, hemoglobin can
be produced at large scale. Yeasts are easy to cultivate and
require cheap substrates in order to produce hemoglobin. It
is also important to note that recombinant hemoglobin is not
associated with the same risks as blood- derived hemoglobin in
terms of pathogens and unstable supply.
All in all, the production of recombinant hemoglobin
can ensure access to safe and affordable blood substitutes
for the entire world population. Ultimately, the production
of recombinant hemoglobin via synthetic biology will
decrease inequality and help reach the goals set by
WHO.
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